Taysha Gene Therapies, Inc. (NasdaqGS:TSHA) acquired Exclusive Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program for $24.8 million on April 12, 2021. Consideration includes upfront payment of $5.5 million and will be eligible to receive clinical, regulatory and commercial milestones totaling up to $19.3 million, as well as a low, single-digit royalty on net sales upon commercialization of the product. AAV9 Gene Therapy is now known as TSHA-120. Taysha Gene Therapies, Inc. (NasdaqGS:TSHA) completed the acquisition of Exclusive Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program on April 12, 2021.